Company intelligence / Profile preview
OPTUS Pharmaceutical
Cheongju, South Koreaoptuspharm.com ↗
- Ownership
- Private
- Employees
- ~159
- Development stage
- Other
01
Overview
OPTUS Pharmaceutical has multiple ophthalmic products approved in South Korea, the EU, and other markets, including dry eye treatments, anti-allergic preparations, glaucoma medications, and presbyopia therapies, with most products being commercial, some in late-stage process development, and a pipeline including generic, new, and combination drugs[3][5][7][9].
- Therapeutic areas
- ImmunologyOphthalmology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Orasis Pharmaceuticals
Beyond the preview
Go deeper on OPTUS Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPTUS Pharmaceutical.